RxDoctor Payments Data

Pamela Cantu, MD

Internal Medicine · Kerrville, TXNPI 1437107901

Payments from drug & device makers

$284in general payments, 2019–2025

Across 16 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$74
  • GSK$45
  • AstraZeneca$43
  • Amgen$33
  • Novo Nordisk$24
  • Inspire Medical Systems, Inc.$24
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$284 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$202,967
Medicare patients
521
Services billed
2,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlassiaAlpha-1-Proteinase Inhibitor12$123,920
OzempicSemaglutide87$114,992
EliquisApixaban159$113,299
JardianceEmpagliflozin86$94,407
MounjaroTirzepatide40$43,917
FarxigaDapagliflozin Propanediol40$37,402
JanuviaSitagliptin Phosphate25$35,272
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,961
XareltoRivaroxaban25$22,067
MyrbetriqMirabegron29$21,164
TradjentaLinagliptin23$16,742
LinzessLinaclotide27$15,178
Combivent RespimatIpratropium/Albuterol Sulfate13$12,738
TrulicityDulaglutide13$10,054
Aimovig AutoinjectorErenumab-Aooe12$9,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$24$114,99287 claims
Lilly USA, LLCMounjaro, Trulicity$18$53,97153 claims
AstraZenecaFarxiga$43$37,40240 claims
GSKTrelegy Ellipta$45$24,96133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Kerrville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →